# Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

> **NCT07733050** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai General Hospital, China** · enrollment: 34 (estimated)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Serplulimab and Bevacizumab injection
- **DRUG:** FOLFIRINOX/NALIRIFOX
- **DRUG:** S-1

## Key facts

- **NCT ID:** NCT07733050
- **Lead sponsor:** Shanghai General Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2027-08-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07733050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07733050, "Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07733050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*